Item InformationBrentuximab vedotin is an ADC composed of an auristatin analog, monomethylauristatin-E (MMAE) conjugated to an anti-CD30 Ab through a protease cleavable linker. This ADC has been shown to cause continuous positive responses in suppressing tumor regression in majority of patients with relapsed or refractory CD30+ lymphomas. Currently, several auristatin analogous have been deployed as ADC payloads in clinical trials, including MMAF and a newly developed dolastatin 10 analogue PF-06380101.
45-1 Ramsey Road, Shirley, NY 11967, USA
Contact Name: Bella Smith